Phio Pharmaceuticals Presents Data at ESMO 2021 Demonstrating Persistent Anti-Tumor Immunity with INTASYL Dual-Targeting PD-1 and BRD4

Sep 16, 2021 | Press Releases

Local treatment with PD-1 and BRD4 dual-targeting INTASYL also showed complete resolution of tumors in vivoMARLBOROUGH, Mass., Sept. 16, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology...

Phio Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference September 13th-15th

Sep 3, 2021 | Press Releases

MARLBOROUGH, Mass., Sept. 3, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Pharmaceuticals Announces Upcoming Data Presentation at the ESMO Virtual Congress 2021

Aug 31, 2021 | Press Releases

MARLBOROUGH, Mass., Aug. 31, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update

Aug 12, 2021 | Press Releases

MARLBOROUGH, Mass., Aug. 12, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Pharmaceuticals Scheduled to Participate in a Fireside Chat with H.C. Wainwright on July 12th

Jul 7, 2021 | Press Releases

MARLBOROUGH, Mass., July 7, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...